Marché mondial des médicaments pour la gestion du stress – Tendances et prévisions de l'industrie jusqu'en 2028

Analyse et perspectives du marché : Marché mondial des médicaments pour la gestion du stress

Le marché des médicaments pour la gestion du stress devrait connaître une croissance exponentielle au cours de la période de prévision de 2021 à 2028. Data Bridge Market Research analyse que le marché connaît une croissance de 4,40 % au cours de la période de prévision de recherche susmentionnée. Le nombre de personnes souffrant de stress dans le monde augmente et les modes de vie changent.

De plus, l'augmentation du soutien gouvernemental au développement de médicaments et la présence de nouveaux produits dans le pipeline stimulent également la croissance du marché. De plus, l'augmentation des dépenses de santé et la demande croissante d'options de traitement efficaces constituent une opportunité pour la croissance du marché. Cependant, les effets indésirables causés par les médicaments antipsychotiques , les réglementations strictes et la disponibilité des traitements à base de plantes et de la méditation peuvent parfois entraver le marché mondial des médicaments de gestion du stress.

Le stress est la réponse du corps à tout changement qui nécessite une réaction et un ajustement. Le corps répond à ces changements en produisant des réponses mentales, physiques et émotionnelles. Le stress peut entraîner plusieurs autres maladies et aggraver la vie d'une personne. Le stress chronique peut entraîner de l'irritabilité, de l'anxiété, de la dépression, des maux de tête et de l'insomnie, entre autres. Le système nerveux central joue un rôle important dans le développement du stress en régulant le niveau hormonal.

Il a été rapporté que le stress peut entraîner plusieurs types de problèmes cardiovasculaires et respiratoires, ce qui représente un risque plus élevé pour la vie.

Selon la publication du NCBI en 2020, le taux de prévalence du stress est de 29,6 % et augmente avec l'augmentation des cas de COVID-19 et devrait donc assurer au marché une croissance lucrative. On estime également que le marché des médicaments de gestion du stress connaîtra un TCAC de 4,40 % en 2020.

This stress management drug market provides details of market share, new developments and product pipeline analysis, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, product approvals, strategic decisions, product launches, geographic expansions and technological innovations in the market. To understand the analysis and the market scenario contact us for an Analyst Brief, our team will help you create a revenue impact solution to achieve your desired goal.

Global Stress Management Drug Market Scope and Market Size

Stress management drug market is segmented on the basis of drug type, type, application, age, end-users and distribution channel. The growth among segments helps you analyse niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.

On the basis of drug type, the stress management drug market is segmented into antidepressant drugs, atypical antipsychotics, benzodiazepines medicals. Antidepressant drugs is further sub- segmented into selective serotonin reuptake inhibitors (SSRIs), serotonin-noradrenaline reuptake inhibitors (SNRIs), noradrenaline and specific serotonergic antidepressants (NASSAs), tricyclic antidepressants (TCAs), monoamine oxidase inhibitors (MAOIs), others. Atypical antipsychotics is further sub- segmented into olanzapine, clozapine, asenapine, quetiapine, paliperidone, risperidone, lurasidone, brexpiprazole, aripiprazole, pimavanserin, iloperidone, others. Benzodiazepines medicals segment is further sub- segmented into diazepam, oxazepam, lorazepam, clorazepate, chlordiazepoxide, alprazolam, temazepam among others.

• On the basis of type, the stress management drug market is segmented into branded and generics.
• On the basis of application, the stress management drug market is segmented into uncomplicated UTIs, healthcare-associated UTIs.
• On the basis of end-users, the stress management drug market is segmented into specialty clinic, hospitals, homecare, others.
• On the basis of distribution channel, the stress management drug market has also been segmented into direct tender, hospital pharmacy, retail pharmacy, online pharmacy and others.

Stress Management Drug Market Country Level Analysis

Stress management drug market is analysed and market size information is provided by country, type, application, organism type, sex, route of administration, end-users and distribution channel as referenced above.

The countries covered in the stress management drug market report are U.S., Canada, Mexico in North America, Brazil, Argentina, Peru, Rest of South America, as part of South America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia-Pacific, Saudi Arabia, U.A.E, Egypt, Israel, Kuwait, South Africa, Rest of Middle East and Africa, as a part of Middle East and Africa.

North America accounts the largest market share due to the increasing disposable income and increasing number of stress sufferers. Europe accounts the second largest market share due to increasing awareness for several types of causes associated with stress development and presence of wide distribution network. Asia-Pacific is expected to account for the largest market share over coming years for the stress management drug market due to constant rise in adoption of changing lifestyles and increasing demand of effective treatment options.

The country section of the report also provides individual market impacting factors and changes in regulations in the market domestically that impacts the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, disease epidemiology and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of sales channels are considered while providing forecast analysis of the country data.

Patient Epidemiology Analysis

Stress management drug market also provides you with detailed market analysis for patient analysis, prognosis and cures. Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the report. Direct or indirect impact analysis of epidemiology to market growth are analysed to create a more robust and cohort multivariate statistical model for forecasting the market in the growth period.

Competitive Landscape and Stress Management Drug Market Share Analysis

Stress management drug market competitive landscape provides details by competitor. details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, company strengths and weaknesses, product launch, clinical trials pipelines, product approvals, patents, product width and breadth, application dominance, technology lifeline curve. The above data points provided are only related to the companies’ focus related to stress management drug market.

Français Les principaux acteurs couverts sur le marché des médicaments de gestion du stress sont Johnson & Johnson Services, Inc., Eli Lilly and Company, AstraZeneca, Pfizer Inc., Otsuka America Pharmaceutical, Inc., Sunovion Pharmaceuticals Inc., Tecoland Corporation, ANGLE BIO PHARMA, Recipharm AB, H. Lundbeck A/S, Teva Pharmaceutical Industries Ltd, Dr. Reddy's Laboratories Ltd, Lannett, ALKERMES, Aurobindo Pharma USA, Sandoz AG, Genentech, USA Inc., Sun Pharmaceutical Industries Ltd., Alvizia Health Care, F. Hoffmann-La Roche Ltd, entre autres acteurs nationaux et mondiaux. Les analystes de DBMR comprennent les atouts de la concurrence et fournissent une analyse concurrentielle pour chaque concurrent séparément.

SKU-59099